New Hampshire Expands ‘Right to Try,’ Boosting Experimental Treatment Access - Governing
New Hampshire expanded its Right to Try law, allowing terminally ill patients broader access to experimental treatments not yet FDA-approved. This may affect pharmaceutical manufacturers by increasing demand for investigational drugs and potentially altering supply chains for unapproved therapies.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) operating in or supplying New Hampshire should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline; monitor for implementation details and potential liability issues.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New Hampshire's Right to Try law now permits terminally ill patients to access investigational drugs, biologics, and devices without FDA approval, under certain conditions.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) operating in or supplying New Hampshire
What you must do
Review current policies on providing investigational drugs to patients under Right to Try laws; ensure compliance with state-specific requirements and federal limitations (e.g., FDA's expanded access programs).
Deadline
No immediate deadline; monitor for implementation details and potential liability issues.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- GLP‑1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters - JD Supra
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines